Seeking Alpha13/11/2026 10:19:54

Cytosorbents outlines early 2027 DrugSorb-ATR De Novo plan with $300M initial U.S./Canada market

Cytosorbents outlines early 2027 DrugSorb-ATR De Novo plan with $300M initial U.S./Canada market

26 min ago
View Original Source
Seeking Alpha

Seeking Alpha

Seeking Alpha is the leading platform for investors to research and discuss US-traded stocks and ETFs. Our platform helps investors to find successful investing ideas and to successfully manage their portfolios. It provides investment ideas, analysis, news, ratings, investing tools and community discussion.

More from Seeking Alpha

Molson Coors: The Valuation Makes Little Sense Even After The Guidance Cut

12 min ago

NeuroPace expects ~15% RNS growth in 2027 as it revises 2026 revenue guidance to $91M-$92M

15 min ago

Cibus targets biofragrance peak revenue up to $100M while aiming for rice launch as early as 2028

15 min ago

NeuroPace, Inc. (NPCE) Q3 2026 Earnings Call Transcript

16 min ago